Daniel Von Hoff, M.D., F.A.C.P is a Distinguished Professor at the Translational Genomics Research Institute (TGen) and at City of Hope and Professor at the Mayo Clinic. He is a Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital in California. Dr. Von Hoff is the past President of the American Association for Cancer Research (AACR).
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 778 papers, 143 book chapters and over 1189 abstracts.
Dr. Von Hoff received his medical degree from the Columbia College of Physicians and Surgeons in New York and completed his residency at the University of California, San Francisco and his fellowship in oncology at the National Cancer Institute.